
Robert Harrington MD
Interventional Cardiology
Stephen and Suzanne Weiss Dean, Weill Cornell Medicine and Provost for Medical Affairs, Cornell University
Join to View Full Profile
1300 York Ave F113New York, NY 10065
Phone+1 212-746-6005
Dr. Harrington is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 1990 - 1993
- UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1989
- Tufts University School of MedicineClass of 1986
Certifications & Licensure
- CA State Medical License 2012 - 2025
- NY State Medical License 2023 - 2025
- NC State Medical License 1993 - 2017
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Clinical Trial to Demonstrate the Efficacy of Cangrelor Start of enrollment: 2006 Apr 01
- Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Start of enrollment: 2006 Sep 01
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Start of enrollment: 2006 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Approach to the Postmarket Evaluation of Consumer Wearable Technologies.Krishna Pundi, Sanjeev Bhavnani, Clark Seninger, Bram Zuckerman, Jessica Paulsen
JAMA Cardiology. 2025-09-10 - Blood Pressure Measurement in Retail Stores and Population Health.Sadiya S Khan, Robert A Harrington, Faraz S Ahmad
JAMA Cardiology. 2025-08-06 - 1 citationsOral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).C Michael Gibson, M Cecilia Bahit, Roxana Mehran, Shamir R Mehta, Rasha Al Lamee
American Heart Journal. 2025-07-01
Journal Articles
- Alirocumab and Cardiovascular Outcomes After Acute Coronary SyndromeVera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
- Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
- Effects of Genetic Variation in Protease Activated Receptor 4 After an Acute Coronary Syndrome: Analysis from the TRACER TrialPaolo Fortina, David J Moliterno, Robert A Harrington, Kenneth W Mahaffey, ScienceDirect
Press Mentions
- July 25 2025 This Week in CardiologyJuly 25th, 2025
- This Week in CardiologyJune 27th, 2025
- Using Data and AI to Create Better Health Care SystemsJune 26th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: